Business
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal second quarter ended October 31, 2025 (“FQ2 2026”) and provided a business update. Second Quarter and Recent Highlights During the second quarter and subsequent per
About this update from Heartsciences Inc.
[{"type":"image","alt":"HeartSciences Inc.","displaySize":"","headline":null,"caption":"HeartSciences Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":271,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/bb8c6c7931166e53de866ed1f7dbdc1d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TQBZp3ueg1_7du_2jEqWig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/bb8c6c7931166e53de866ed1f7dbdc1d","width":271,"height":58}},"lazy":false},{"type":"text","content":"Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal second quarter ended October 31, 2025 (“FQ2 2026”) and provided a business update.","length":418,"tagName":"p"},{"type":"text","content":"Second Quarter and Recent Highlights","length":36,"tagName":"p"},{"type":"text","content":"During the second quarter and subsequent period, the Company made significant progress in the commercialization and advancement of its MyoVista Insights™ healthcare IT platform and submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance.","length":300,"tagName":"p"},{"type":"text","content":"MyoVista Insights™ Healthcare IT Software","length":41,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"MyoVista Insights is classified as a Medical Device Data System (“MDDS”), which carries significantly lower regulatory requirements and is exempt from 510(k) clearance. As a result, the organizational costs and speed of commercial rollout are expected to be substantially lower and faster than those associated with regulated medical devices.","length":342,"tagName":"p"}]},{"val":[{"type":"text","content":"Since its launch in May 2025, and following the recent release of Version 1.1, MyoVista Insights has received strong validation from early adopters. The Company is currently engaged in commercial discussions with several healthcare institutions for deployment and expects to announce multiple key customer wins in the near term.","length":328,"tagName":"p"}]},{"val":[{"type":"text","con...